Crenolanib
| CAS No. | 670220-88-9 |
|---|---|
| MDL No. | MFCD21609260 |
| MF | C26H29N5O2 |
| MW | 443.50 |
| InChI Key | DYNHJHQFHQTFTP-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Crenolanib is a benzimidazole derivative with a 1H-benzimidazole core substituted at position 1 by an 8-(4-aminopiperidin-1-yl)quinolin-2-yl group and at position 5 by a (3-methyloxetan-3-yl)methoxy group. It inhibits type III tyrosine kinases, including PDGFRalpha/beta and FLT3, with IC50 values of 11, 3.2, and 4 nM, respectively. Under clinical development for acute myeloid leukemia, it functions as a receptor protein-tyrosine kinase inhibitor, angiogenesis inhibitor, antineoplastic agent, and apoptosis inducer. It belongs to benzimidazoles, aromatic ethers, quinolines, oxetanes, aminopiperidines, and tertiary amino compounds.
| CAS No. | 670220-88-9 |
|---|---|
| Product Name | Crenolanib |
Biological Targets
PDGFRB·PDGFRA·FLT3
Associated Conditions
diffuse intrinsic pontine glioma·Paraganglioma·gastrointestinal stromal tumor·neoplasm·acute myeloid leukemia·
* The information provided here is compiled from public sources and is for reference only.
